NCM
CERE

Nantahala Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Nantahala Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-685,704
Closed -$11.4M – 136
2020
Q4 		$11.4M Buy
+685,704
New +$8.91M 0.35% 60

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Nantahala Capital Management's CERE Position: Q1 2021 in Review

Nantahala Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2021, closing a stake of 685,704 shares — an estimated $11.4M sold.

Nantahala Capital Management first reported a position in CERE in Q4 2020 and held it in 1 quarter. The position peaked at $11.4M in Q4 2020. 62 funds tracked by Wall St. Rank hold CERE as of Q1 2021.

  • Nantahala Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Nantahala Capital Management sold 685,704 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2021, an estimated $11.4M.
  • Nantahala Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Nantahala Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $11.4M in Q4 2020.
  • 62 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2021.

Based on Nantahala Capital Management's 13F filing for Q1 2021, filed 14 May 2021.